Thomas Edward Gibbs Net Worth

The estimated Net Worth of Thomas Edward Gibbs is at least $18.9 Tausend dollars as of 7 March 2019. Thomas Gibbs owns over 2,000 units of OptiNose Inc stock worth over $2,388 and over the last 10 years Thomas sold OPTN stock worth over $16,480.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Gibbs OPTN stock SEC Form 4 insiders trading

Thomas has made over 2 trades of the OptiNose Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Thomas sold 2,000 units of OPTN stock worth $16,480 on 7 March 2019.

The largest trade Thomas's ever made was selling 2,000 units of OptiNose Inc stock on 7 March 2019 worth over $16,480. On average, Thomas trades about 571 units every 29 days since 2015. As of 7 March 2019 Thomas still owns at least 2,596 units of OptiNose Inc stock.

You can see the complete history of Thomas Gibbs stock trades at the bottom of the page.

What's Thomas Gibbs's mailing address?

Thomas's mailing address filed with the SEC is 2200 PENNSYLVANIA AVE NW, , WASHINGTON, DC, 20037.

Insiders trading at OptiNose Inc

Over the last 19 years, insiders at OptiNose Inc have traded over $144,654,703 worth of OptiNose Inc stock and bought 116,688 units worth $814,936 . The most active insiders traders include Sriram Venkataraman, Capital Partners Ii Gp, Llc... und Rajat Rai. On average, OptiNose Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,645. The most recent stock trade was executed by Anthony J Krick on 17 July 2024, trading 6,845 units of OPTN stock currently worth $7,803.

What does OptiNose Inc do?

optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo

Complete history of Thomas Gibbs stock trades at Vanda Pharmaceuticals Inc und OptiNose Inc

OptiNose Inc executives and stock owners

OptiNose Inc executives and other stock owners filed with the SEC include:

• Peter Miller,
  Chief Executive Officer, Director
• Ramy Mahmoud,
  President, Chief Operating Officer
• Michael Marino,
  Chief Legal Officer and Corporate Secretary
• Peter K. Miller,
  CEO & Director
• Keith Goldan,
  Chief Financial Officer
• Dr. Ramy A. Mahmoud M.D., M.P.H.,
  Pres & COO
• Michael F. Marino,
  Chief Legal Officer & Corp. Sec.
• Keith Alan Goldan,
  Chief Financial Officer
• Victor M. Clavelli,
  Chief Commercial Officer
• Michael F. Marino Esq.,
  Chief Legal Officer & Corp. Sec.
• Joseph Scodari,
  Independent Chairman of the Board
• Sandra Helton,
  Independent Director
• Wilhelmus Groenhuysen,
  Independent Director
• William Doyle,
  Independent Director
• Jonathan Neely,
  VP Investor Relations and Business Operations
• Catherine Owen,
  Director
• Victor Clavelli,
  Chief Commercial Officer
• Anthony Krick,
  VP & Chief Accounting Officer
• Michele Janis MBA,
  VP & Acting CFO
• Dr. Per Gisle Djupesland M.D., Ph.D.,
  Co-Founder & Chief Scientific Officer of OptiNose AS
• Helena Kyttari Djupesland,
  Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)
• John Messina,
  Sr. VP of Clinical Devel. & Medical Affairs
• Karen E. Brophy,
  VP of HR
• Paul Mastrapa,
  CFO
• John N Kapoor,
  Director
• Edward A Blechschmidt,
  Director
• Leo Henikoff,
  Director
• Kenneth Abramowitz,
  Director
• Jerome Sheldon,
  Director
• Rajat Rai,
  CEO
• Joseph Bonaccorsi,
  Secretary
• Richard M Smith,
  President & COO
• Capital Partners Ii Gp, Llc...,
  
• Ventures Llctkwd Ventures L...,
  
• Fund Lp Entrepreneurs Fund ...,
  
• Rick Bierly,
  Director
• Sriram Venkataraman,
  Director
• Larry G Pickering,
  Director
• Thomas Edward Gibbs,
  Chief Commercial Officer
• Joshua Alexander Tamaroff,
  Director
• Robert P O'neil,
  Director
• Ventures Llc Wfd,
  10% owner
• Ventures Llc Tkwd,
  10% owner
• Anthony J Krick,
  Chief Accounting Officer
• Tomas J. Heyman,
  Director
• Kyle Dempsey,
  Director
• Eric Bednarski,
  Director
• R John Fletcher,
  Director
• Paul Jr. Spence,
  Chief Commercial Officer
• Michele Janis,
  Acting Chief Financial Officer